Insertional mutagenesis reveals progression genes and checkpoints in MYC/Runx2 lymphomas.

In this study, we have exploited the power of insertional mutagenesis to elucidate tumor progression pathways in mice carrying two oncogenes (MYC/Runx2) that collaborate to drive early lymphoma development. Neonatal infection of these mice with Moloney murine leukemia virus resulted in accelerated tumor onset with associated increases in clonal complexity and lymphoid dissemination. Large-scale analysis of retroviral integration sites in these tumors revealed a profound bias towards a narrow range of target genes, including Jdp2 (Jundm2), D cyclin, and Pim family genes. Remarkably, direct PCR analysis of integration hotspots revealed that every progressing tumor consisted of multiple clones harboring hits at these loci, giving access to large numbers of independent insertion events and uncovering the contrasting mutagenic mechanisms operating at each target gene. Direct PCR analysis showed that high-frequency targeting occurs only in the tumor environment in vivo and is specific for the progression gene set. These results indicate that early lymphomas in MYC/Runx2 mice remain dependent on exogenous growth signals, and that progression can be achieved by constitutive activation of pathways converging on a cell cycle checkpoint that acts as the major rate-limiting step for lymphoma outgrowth.

[1]  Takeshi Suzuki,et al.  Tumor suppressor gene identification using retroviral insertional mutagenesis in Blm‐deficient mice , 2006, The EMBO journal.

[2]  Yoshiaki Ito,et al.  Pim-1 kinase phosphorylates RUNX family transcription factors and enhances their activity , 2006, BMC Cell Biology.

[3]  M. Horikoshi,et al.  Regulation of histone acetylation and nucleosome assembly by transcription factor JDP2 , 2006, Nature Structural &Molecular Biology.

[4]  K. Shokat,et al.  The Cyclin-Dependent Kinase (CDK) Family Member PNQALRE/CCRK Supports Cell Proliferation but has no Intrinsic CDK-Activating Kinase (CAK) Activity , 2006, Cell cycle.

[5]  K. Blyth,et al.  Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo. , 2006, Cancer research.

[6]  Brian T Luke,et al.  Redefining the common insertion site. , 2006, Virology.

[7]  E. Musgrove.  Cyclins: Roles in mitogenic signaling and oncogenic transformation , 2006, Growth factors.

[8]  A. Berns,et al.  Retroviral insertional mutagenesis: past, present and future , 2005, Oncogene.

[9]  F. Pedersen,et al.  Tumor model-specific proviral insertional mutagenesis of the Fos/Jdp2/Batf locus. , 2005, Virology.

[10]  Karen Blyth,et al.  The runx genes: gain or loss of function in cancer , 2005, Nature Reviews Cancer.

[11]  T. Möröy,et al.  The serine/threonine kinase Pim-1. , 2005, The international journal of biochemistry & cell biology.

[12]  S. Ely,et al.  Homeostatic cell-cycle control by BLyS: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Aronheim,et al.  The c-Jun Dimerization Protein 2 Inhibits Cell Transformation and Acts as a Tumor Suppressor Gene* , 2004, Journal of Biological Chemistry.

[14]  Wenyi Wei,et al.  Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. , 2002, Biochimica et biophysica acta.

[15]  K. Blyth,et al.  Proviral insertion indicates a dominant oncogenic role for Runx1/AML-1 in T-cell lymphoma. , 2002, Cancer research.

[16]  S. Kingsman,et al.  Cytochrome P450-based cancer gene therapy: current status , 2002, Expert opinion on biological therapy.

[17]  D. Naiman,et al.  New genes involved in cancer identified by retroviral tagging , 2002, Nature Genetics.

[18]  K. Blyth,et al.  Enforced Expression of Runx2 Perturbs T Cell Development at a Stage Coincident with β-Selection1 , 2002, The Journal of Immunology.

[19]  Danielle Hulsman,et al.  Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice , 2002, Nature Genetics.

[20]  Anton Berns,et al.  High-throughput retroviral tagging to identify components of specific signaling pathways in cancer , 2002, Nature Genetics.

[21]  D. Gilliland,et al.  Core-binding factors in haematopoiesis and leukaemia , 2002, Nature Reviews Cancer.

[22]  E. Cameron,et al.  The Common Retroviral Insertion Locus Dsi1 Maps 30 Kilobases Upstream of the P1 Promoter of the Murine Runx3/Cbfa3/Aml2 Gene , 2002, Journal of Virology.

[23]  B. Clurman,et al.  high-throughput insertion site analysis , 2002 .

[24]  J. Massagué,et al.  Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. , 2002, Nature.

[25]  Carl W. Miller,et al.  Mutations in the mitotic check point gene, MAD1L1, in human cancers , 2001, Oncogene.

[26]  Andrius Kazlauskas,et al.  Growth-factor-dependent mitogenesis requires two distinct phases of signalling , 2001, Nature Cell Biology.

[27]  K. Blyth,et al.  Runx2: A novel oncogenic effector revealed by in vivo complementation and retroviral tagging , 2001, Oncogene.

[28]  E. Seto,et al.  A Mechanism of Repression by Acute Myeloid Leukemia-1, the Target of Multiple Chromosomal Translocations in Acute Leukemia* , 2000, The Journal of Biological Chemistry.

[29]  S. Knuutila,et al.  AML1 gene amplification: a novel finding in childhood acute lymphoblastic leukemia. , 2000, Haematologica.

[30]  K. Blyth,et al.  A full-length Cbfa1 gene product perturbs T-cell development and promotes lymphomagenesis in synergy with MYC , 1999, Oncogene.

[31]  J. Downward,et al.  Multiple Ras Effector Pathways Contribute to G1Cell Cycle Progression* , 1999, The Journal of Biological Chemistry.

[32]  M. Mann,et al.  Cell cycle progression: new therapeutic target for vascular proliferative disease. , 1998, Circulation.

[33]  E. Baxter,et al.  Proviral insertions induce the expression of bone-specific isoforms of PEBP2alphaA (CBFA1): evidence for a new myc collaborating oncogene. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Elledge,et al.  Isolation of an AP-1 repressor by a novel method for detecting protein-protein interactions , 1997, Molecular and cellular biology.

[35]  L. Donehower,et al.  Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development? , 1996, Journal of virology.

[36]  J.M. Adams,et al.  Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. , 1994, The EMBO journal.

[37]  W. Anderson,et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation , 1993, The Lancet.

[38]  S. Cory,et al.  Oncogene co-operation in leukaemogenesis. , 1992, Cancer surveys.

[39]  Anton Berns,et al.  Identification of cooperating oncogenes in Eμ-myc transgenic mice by provirus tagging , 1991, Cell.

[40]  A. Berns,et al.  Mice bearing the E mu-myc and E mu-pim-1 transgenes develop pre-B-cell leukemia prenatally , 1991, Molecular and cellular biology.

[41]  W. S. Hayward,et al.  Multiple proto-oncogene activations in avian leukosis virus-induced lymphomas: evidence for stage-specific events , 1989, Molecular and cellular biology.

[42]  M. Zijlstra,et al.  Tumor progression in murine leukemia virus-induced T-cell lymphomas: monitoring clonal selections with viral and cellular probes , 1986, Journal of virology.

[43]  R. Palmiter,et al.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice , 1985, Nature.

[44]  L. Kaczmarek,et al.  Microinjected c-myc as a competence factor. , 1985, Science.

[45]  P. Leder,et al.  Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes , 1984, Cell.

[46]  Wim Quint,et al.  Murine leukemia virus-induced T-cell lymphomagenesis: Integration of proviruses in a distinct chromosomal region , 1984, Cell.